Plenty of cash for Peplin

By Kate McDonald
Tuesday, 02 December, 2008

Australian-US biotech Peplin has reported a healthy cash balance of US$12.8 million, in addition to a recent private placement of US$24 million.

Releasing its financial results for the quarter ended September 30 to the ASX, Peplin said it believed the balance would be sufficient to fund Phase III trials of its topical ingenol mebutate, PEP005.

PEP005 is aimed at treating solar actinic keratoses on the head and body. Peplin recently began a Phase III trial in non-head applications.

The company said it was on track to report results of its Phase IIb trial in head applications in the first quarter of 2009.

Related News

Next-gen therapies could treat high-grade gliomas

Government funding will enable researchers to test a suite of next-generation therapies they have...

Bacteriophage cocktail to combat superbugs

Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...

Exclusive colostrum intake may reduce risk of food allergies

Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd